Natco Pharma Ltd
NSE:NATCOPHARM
Operating Margin
Natco Pharma Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Natco Pharma Ltd
NSE:NATCOPHARM
|
143.1B INR |
46%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
236.5B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
36%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.7B CHF |
32%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
25%
|
Natco Pharma Ltd
Glance View
Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations. Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Natco Pharma Ltd's most recent financial statements, the company has Operating Margin of 45.7%.
You don't have any saved screeners yet